Revenue ($m) 208.8, down 8.1pc from year-earlier 227.2
Pretax profit ($m) -229.3 v -25
Net profit ($m) -181.7 v -19.3
No interim dividend
Specialty pharmaceutical company Mayne Pharma Group hopes to get the nod from US regulators by April for its novel oral contraceptive, Nextstellis.
The company is waiting on several key approvals for major products at the US Food and Drug Administration, including its Nextstellis, a generic version of Nuvaring. Rival Teva Pharmaceuticals has won FDA approval for its generic Nuvaring, heaping more pressure on Mayne to win approval.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
